Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia [Phase 4]
Phase 4 study evaluating valbenazine for tardive dyskinesia in participants with schizophrenia, schizoaffective disorder, bipolar disorder, …
-
CLINICAL_TRIALS trial_result · 2026-01-15Clinical Trial Update: A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women [Phase 1]
Phase 1 clinical trial evaluating potential interactions between SEP-380135 and other drugs in healthy adults, which has completed.
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia [EARLY_Phase 1]
Phase 1 study evaluating single and multiple ascending doses of NTX-253 in healthy participants and in individuals with stable schizophrenia…
-
FDA approval · 2026-01-14FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for a fixed-dose combination of olanzapine and fluoxetine, enabling generic marketing of the pr…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia [Phase 3]
This is a Phase 3 long-term administration trial of SEP-363856 in patients with schizophrenia that is currently recruiting, sponsored by Ots…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia [Phase 1]
Open-label Phase 1 study comparing the bioavailability of TV-44749 to oral olanzapine in participants with schizophrenia; the trial status i…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
A clinical trial investigating the role of tryptophan-kynurenine pathway metabolism in cognitive impairment associated with schizophrenia, c…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Intermittent Theta Burst Stimulation of the Precuneus [NA]
An update on a clinical trial evaluating intermittent theta burst stimulation of the precuneus for schizophrenia; the study is not yet recru…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Effects of Transcranial Direct Current Stimulation on Cognitive Rehabilitation in Schizophrenia [NA]
A clinical trial investigating the effects of transcranial direct current stimulation on cognitive rehabilitation in individuals with schizo…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Interest of the Tool: Evaluation of Specific Care in an Ecological Environment for Patients Suffering From Schizophrenia-like Disorders [NA]
This clinical trial update shows a study sponsored by Centre Hospitalier Henri Laborit that is recruiting to evaluate a specific care tool i…
-
EMA approval · 2026-01-12EMA Authorised: Latuda (lurasidone) — Aziende Chimiche Riunite Angelini Francesco S.p.A.
The European Medicines Agency authorised Latuda (lurasidone) for schizophrenia, with Aziende Chimiche Riunite Angelini Francesco S.p.A. as t…
-
EMA approval · 2026-01-12EMA Authorised: Abilify (aripiprazole) — Otsuka Pharmaceutical Netherlands B.V.
The EMA authorised Abilify (aripiprazole) by Otsuka Pharmaceutical Netherlands B.V. for schizophrenia and bipolar disorder in the European U…
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet? [NA]
A completed clinical trial (NCT05268809) examined whether a very low-carbohydrate ketogenic diet could improve neural network instability in…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Circuitry-Guided Smoking Cessation in Schizophrenia (UH3) [NA]
This clinical trial update shows that the UH3 study on circuitry-guided smoking cessation in people with schizophrenia is currently recruiti…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Randomized Withdrawal Study in Patients With Schizophrenia [Phase 3]
Phase 3 randomized withdrawal trial in schizophrenia sponsored by Vanda Pharmaceuticals; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: Cinematic Virtual Reality Intervention for Improving Psychosocial Functioning in Individuals With Schizophrenia [NA]
This entry reports the completion of a clinical trial evaluating a cinematic virtual reality intervention to improve psychosocial functionin…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia [Phase 3]
Phase 3 study of TV-44749 in adults with schizophrenia completed, with results posted. The trial used a randomized, double-blind, placebo-co…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: TMS Related Biomarker Assessments [NA]
A clinical trial update reports transcranial magnetic stimulation–related biomarker assessments; the study (NCT05660018) in schizophrenia an…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia [NA]
Status is COMPLETED for a trial evaluating virtual reality-based psychotherapy targeting negative symptoms in schizophrenia.
-
EMA approval · 2026-01-08EMA Authorised: Reagila (cariprazine hydrochloride) — Gedeon Richter
The European Medicines Agency authorised Reagila (cariprazine) for schizophrenia, with Gedeon Richter as the marketing authorisation holder …
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis [Phase 3]
A Phase 3 trial is evaluating cannabidiol as an adjunct to standard treatment for early psychosis, comparing CBD to placebo; the study is cu…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic [NA]
This clinical trial update describes the Meta Care Clinic, a pragmatic metabolic care program for patients with severe mental illness, with …
-
EMA approval · 2026-01-07EMA Authorised: Olanzapine Viatris (previously Olanzapine Mylan) (olanzapine) — Viatris Limited
The EMA has authorised Olanzapine Viatris for schizophrenia and bipolar disorder; the marketing authorization holder is Viatris Limited.
-
FDA approval · 2026-01-07FDA Approved: QUETIAPINE — Supplemental Application (Accord Healthcare Inc.)
The FDA approved Accord Healthcare Inc.'s supplemental application for quetiapine (generic), indicating approval of a modification to an alr…
-
FDA approval · 2026-01-06FDA Approved: OLANZAPINE — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for Olanzapine submitted by Strides Pharma Science Limited. This action approves a supplemental …